Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

3(33%)

Phase Distribution

Ph phase_2

56%

Ph phase_1

11%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

1(11.1%)

Phase 2Efficacy & side effects

5(55.6%)

Phase 3Large-scale testing

3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(4)

Other(3)

Detailed Status

Terminated3

Completed2

unknown2

Suspended1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (11.1%)

Phase 25 (55.6%)

Phase 33 (33.3%)

Trials by Status

terminated333%

completed222%

suspended111%

withdrawn111%

unknown222%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_1

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

NCT00002787

withdrawnphase_2

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

NCT00621036

unknownphase_2

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

NCT00258336

completedphase_2

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

NCT00071955

suspendedphase_3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT00002787Phase 1

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Completed

NCT00621036Phase 2

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Withdrawn

NCT00258336Phase 2

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Unknown

NCT00071955Phase 2

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Completed

NCT00324831Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended

NCT00017290Phase 3

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

Unknown

NCT00089115Phase 3

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Terminated

NCT00104819Phase 2

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

Terminated

NCT00510471Phase 2

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Terminated

All 9 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 9